AZUR-2: Perioperative Dostarlimab in Patients with dMMR/MSI-H Resectable Colon Cancer
Condition: Colon Cancer
Sponsor: GlaxoSmithKline
Full Title
Protocol 219606: A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy versus Standard of Care in Participants with Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
Study Treatment
Perioperative treatment with anti-PD1 monoclonal antibody dostarlimab
Eligibility/Info
- Pathologically confirmed resectable (T4N0 or Stage III) colon adenocarcinoma
- Mismatch repair deficient or MSI-High
- No history of treatment
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
